On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | +9.72% | -11.24% | -78.06% |
May. 16 | AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024 | CI |
May. 16 | AEON Biopharma, Inc. Announces Executive Changes | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
106,900 KRW | +3.69% | -0.56% | 889M | ||
1.58 USD | +9.72% | -11.24% | 61.28M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.06% | 61.28M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.15% | 21.96B | |
-9.40% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd